ArticlePLoS neglected tropical diseases2026
Epidemiological investigation of Shuni virus infections in hospitals in two provinces of South Africa (2019-2021) using molecular and serological surveillance.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shuni Virus (SHUV) is a reemerging zoonotic orthobunyavirus in the Peribunyaviridae family associated with neurological infections and birth defects in humans and animals in Africa and has emerged in the Middle East in the past 10 years. Limited epidemiological data exist in humans, partially due to a lack of clinical awareness and availability of diagnostic assays to determine the incidence of clinical cases and seroprevalence in the population. The goal of this study was to establish serologic and molecular diagnostic assays for SHUV for hospital-based surveillance and to investigate the clinical epidemiology in humans in South Africa. The incidence of SHUV infections was investigated in patients with acute fever of unknown cause with or without neurological signs (AFDUC/N) during the arbovirus season (January-June, 2019-2021). IgM and IgG ELISAs for SHUV were established using baculovirus-expressed glycoproteins and validated against virus-neutralization tests (VNT) positive sera. Orthobunyavirus quantitative RT-PCR (RT-qPCR) and IgM ELISA were used to identify acute infections, and IgG ELISA to define the seroprevalence in patients and healthy control groups in hospitals in Gauteng and Mpumalanga provinces in South Africa. In total, 3/349 (0.84%) AFDUC/N cases tested positive by RT-qPCR and confirmed as SHUV by sequencing. In total, 22/225 (9.7%) AFDUC/N patients had SHUV neutralising antibodies (VNT), of which 11/22 (50.00%) were IgM positive, with an IgM seropositivity of 4.89% (11/225 (4.89%)). Of the RT-PCR and double IgM + VNT+ patients, 60% presented with seizures and 40% with meningitis, of which 36.36% were children and 63.63% were adults, respectively. In total, 9/112 (8%) of the healthy control group tested positive on the IgG ELISA assay. These findings suggest that SHUV is a missed cause of acute neurological infections in hospitalized children and adults in South Africa and should be investigated in humans in Africa and other regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.